University of Notre Dame DU Lac Invests $2.82 Million in Vanda Pharmaceuticals Inc. (VNDA)
University of Notre Dame DU Lac purchased a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 157,781 shares of the biopharmaceutical company’s stock, valued at approximately $2,824,000. University of Notre Dame DU Lac owned about 0.35% of Vanda Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of VNDA. Schwab Charles Investment Management Inc. increased its position in Vanda Pharmaceuticals by 2.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock valued at $8,459,000 after buying an additional 11,647 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Vanda Pharmaceuticals by 112.2% in the 3rd quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after purchasing an additional 80,209 shares in the last quarter. Cadence Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth $1,121,000. Rothschild Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth $23,491,000. Finally, Cortina Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 423.6% in the 3rd quarter. Cortina Asset Management LLC now owns 212,503 shares of the biopharmaceutical company’s stock worth $3,804,000 after purchasing an additional 171,918 shares in the last quarter. Institutional investors and hedge funds own 88.45% of the company’s stock.
Several brokerages recently commented on VNDA. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies lifted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. Jefferies Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $21.50.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at $14.05 on Wednesday. Vanda Pharmaceuticals Inc. has a 52-week low of $11.90 and a 52-week high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The business had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. During the same period in the previous year, the business earned ($0.01) earnings per share. The business’s revenue was up 7.3% on a year-over-year basis. analysts forecast that Vanda Pharmaceuticals Inc. will post -0.42 EPS for the current fiscal year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.